PPHLN1 and neoplasm: Given the reduction in group 3 MB tumoursphere size and number following one-time PPHLN1-Mo treatment and the sustained exon skipping over 15 d in vitro (Fig. 6d), we hypothesized that PPHLN1-Mo would be sufficient to impair tumour initiation and growth in vivo.